Zealand Pharma to Participate in Upcoming Investor Conferences

Press release – No. 3/ 2022

Zealand Pharma to Participate in Upcoming Investor Conferences

Copenhagen, DK and Boston, MA, U.S. June 3, 2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that the company will participate in the following investor conferences in June:

Jefferies 2022 Global Healthcare ConferenceDate: Friday, June 10, 2022Presentation: 8:00 a.m. EST / 12:00 p.m. GMT / 2:00 p.m. CET

Goldman Sachs Global Healthcare ConferenceDate: Monday, June 13, 2022

A live webcast of the Jefferies presentation will be available on the "Events & Presentations" page in the Investor section of the Company's website at https://www.zealandpharma.com/events-presentations. A replay of the webcast will be archived on the Company's website following the presentation.

# # #

About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.

Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com.

For further information, please contact:

Zealand Pharma Investor RelationsMaeve ConneightonArgot Partners[email protected]

Zealand Pharma Media Relations David Rosen Argot Partners[email protected]

You May Also Be Interested In

• Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)
• Simply Good Foods Company Securities Fraud Class Action Result of Undisclosed Acquisition Failures and Over 27% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC
• AEVEX Corp. Notice of October 20, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline